Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Praxis Precision Medicines, Inc. (“Praxis” or “the Company”) (NASDAQ: PRAX). Investors who purchased Praxis securities are encouraged to obtain additional information and assist the investigation.

The investigation concerns whether Praxis has violated federal securities laws.

Investigation Details

On August 4, 2025, Praxis announced its Q2 2025 financial results. The Company reported mid-stage clinical results from the trial of vormatrigine, an anti-seizure medication. Praxis admitted that more than half of patients experienced treatment-emergent adverse events, with almost 25% of study participants discontinuing the medication. Following this news, Praxis stock price dropped more than 5% on the same day.

What’s Next?

If you are aware of any facts relating to this investigation or purchased Praxis securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660